Press Releases

Month Year

Sep 26, 2023

Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for Priority Review
Sep 13, 2023

Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
- Photos 4
Sep 12, 2023

ALTUVIIIO® supplemental biologics license application based on positive final results from Phase 3 XTEND-Kids study accepted by FDA

First-in-class ALTUVIIIO offers clinically proven highly effective bleed protection with once-weekly dosing for children with hemophilia A
Aug 24, 2023

Beyfortus™ (nirsevimab-alip) recommended for routine use to protect infants against RSV disease in CDC Morbidity and Mortality Weekly Report

The recommendation helps to ensure all infants have the opportunity to be protected from RSV disease ahead of the next winter virus season
Aug 3, 2023

U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
Jul 25, 2023

Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
Jul 17, 2023

FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
Jun 25, 2023

ALTUVIIIO™ late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
Jun 8, 2023

FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
Jun 2, 2023

New data from Sanofi’s diverse, differentiated oncology pipeline and portfolio to be presented at ASCO 2023

Show per page

Print
Email page
RSS